Anders Romare, Advisory Board Member, causaLens, and former Novo Nordisk CDIO, outlines why artificial intelligence represents a structural turning point for the pharmaceutical industry.
Anders Romare
Advertisement
Articles by Anders Romare
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Prediction Markets Expose a Gap in Pharmaceutical Vendor Contracts
2
The Bottlenecks That Slow Manufacturer Response to Increased Demand for Production
3
Roundup: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Therapy, Enodia Therapeutics Enters Collaboration and License Agreement to Develop Sec61-Targeting Small Molecules
4
The Manufacturing Issues That Continue to Contribute to Drug Shortages
5